Table 2. The clinicopathological characteristics of patients with invasive ductal.
| Clinicopathological characteristics | Patients, n (%) |
|---|---|
| Age (≤50/ >50 years) | 116(30%)/268(70%) |
| Size (≤20/ 21-50/ >50 mm) | 233(61%)/142(37%)/9(2%) |
| Grade (I / II / III) | 71(19%)/147(38%)/166(43%) |
| Involved lymph node (−ve/+ve) | 209(54%)/172(45%)* |
| ER status (no/yes) | 116(30%)/268(68%) |
| PR status (no/yes) | 152(40%)/230(60%)* |
| Her-2 status (no/ yes) | 305(79%)/70(18%)* |
| Lymphaic vessel invasion (no/yes) | 254(66%)/130(34%) |
| Blood vessel invasion (no/yes) | 340(88%)/44(12%) |
| Tumour necrosis (low/high) | 183(48%)/201(52%) |
| Klintrup–Mäkinen grade (low/high) | 272(71%)/112(29%) |
| CD68+ (low/moderate/high) | 116(30%)/129(34%)/124(32%)* |
| CD4+ (low/moderate/high) | 160(42%)/75(20%)/136(35%)* |
| CD8+ (low/moderate/high) | 124(32%)/119(31%)/128(33%)* |
| CD138+(low/moderate/high) | 203(53%)/45(12%)/122(32%)* |
| Tumour stroma percentage (low/high) | 264(69%)/120(31%) |
| Tumour budding (low/high) | 250(65%)/134(35%) |
| Locoregional treatment (lumpectomy + radiotherapy/mastectomy +radiotherapy) | 143(37%)/241(63%) |
| Systemic treatment (hormonal/hormonal+ chemotherapy/chemotherapy/ none) | 194(51%)/70(18%)/90(23)/24(6%)* |
| Recurrence status (no/yes) | 285(74%)/95(25%)* |
| Alive/cancer death/non cancer death | 228(59%)/82(22%)/74(19%) |
*
Number of patients when incomplete data available.